KR20240108407A - 총상 신경섬유종의 치료 또는 예방에 사용하기 위한 니트록솔린 - Google Patents

총상 신경섬유종의 치료 또는 예방에 사용하기 위한 니트록솔린 Download PDF

Info

Publication number
KR20240108407A
KR20240108407A KR1020247016458A KR20247016458A KR20240108407A KR 20240108407 A KR20240108407 A KR 20240108407A KR 1020247016458 A KR1020247016458 A KR 1020247016458A KR 20247016458 A KR20247016458 A KR 20247016458A KR 20240108407 A KR20240108407 A KR 20240108407A
Authority
KR
South Korea
Prior art keywords
composition
nitroxolin
administered
pharmaceutically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247016458A
Other languages
English (en)
Korean (ko)
Inventor
데이빗 브라운
Original Assignee
힐렉스 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 힐렉스 엘티디 filed Critical 힐렉스 엘티디
Publication of KR20240108407A publication Critical patent/KR20240108407A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247016458A 2021-11-19 2022-11-18 총상 신경섬유종의 치료 또는 예방에 사용하기 위한 니트록솔린 Pending KR20240108407A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2116743.2 2021-11-19
GBGB2116743.2A GB202116743D0 (en) 2021-11-19 2021-11-19 Treatment
PCT/GB2022/052933 WO2023089328A1 (en) 2021-11-19 2022-11-18 Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma

Publications (1)

Publication Number Publication Date
KR20240108407A true KR20240108407A (ko) 2024-07-09

Family

ID=79163954

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247016458A Pending KR20240108407A (ko) 2021-11-19 2022-11-18 총상 신경섬유종의 치료 또는 예방에 사용하기 위한 니트록솔린

Country Status (11)

Country Link
US (1) US20250000852A1 (https=)
EP (1) EP4433054A1 (https=)
JP (1) JP2024540439A (https=)
KR (1) KR20240108407A (https=)
CN (1) CN118215479A (https=)
AU (1) AU2022392456A1 (https=)
CA (1) CA3238805A1 (https=)
GB (1) GB202116743D0 (https=)
IL (1) IL312885A (https=)
MX (1) MX2024006105A (https=)
WO (1) WO2023089328A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218460D0 (en) * 2022-12-08 2023-01-25 Healx Ltd Treatment
WO2026022492A1 (en) * 2024-07-26 2026-01-29 Healx Limited Nitroxoline for use in the treatment and/or prevention of pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641471T3 (es) * 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
GB202108224D0 (en) * 2021-06-09 2021-07-21 Healx Ltd Treatment

Also Published As

Publication number Publication date
AU2022392456A1 (en) 2024-05-23
WO2023089328A1 (en) 2023-05-25
US20250000852A1 (en) 2025-01-02
JP2024540439A (ja) 2024-10-31
CA3238805A1 (en) 2023-05-25
MX2024006105A (es) 2024-05-30
CN118215479A (zh) 2024-06-18
EP4433054A1 (en) 2024-09-25
IL312885A (en) 2024-07-01
GB202116743D0 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
US12263139B2 (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
Ma et al. Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers
KR20240108407A (ko) 총상 신경섬유종의 치료 또는 예방에 사용하기 위한 니트록솔린
Ding et al. Inhibition of dectin-1 alleviates neuroinflammatory injury by attenuating NLRP3 inflammasome-mediated pyroptosis after intracerebral hemorrhage in mice: preliminary study results
KR20210013155A (ko) 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도
US20240261276A1 (en) Nitroxoline for use in the treatment of cutaneous neurofibroma
CN121197400A (zh) 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
JP2018522936A (ja) ぶどう膜黒色腫の処置のためのｍｄｍ２阻害剤
Jia et al. Metformin ameliorates postoperative cognitive dysfunction through regulation of the AMPK/SIRT1 pathway
TW202038960A (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
EP3773538A1 (en) Treatment of fragile x syndrome
KR102141971B1 (ko) 항암용 조성물
Wang et al. Mitigating inflammatory response in breast cancer patients: the inhibitory effect of acupuncture and emotional nursing on the ST8SIA6-AS1/LINC00504/p38 pathway
AU2023391325A1 (en) Nitroxoline for use in the treatment or prevention of a malignant peripheral nerve sheath tumour
US10314831B2 (en) RAC1 inhibitors of neurofibroma formation
CN105878253A (zh) 科罗索酸的医药用途
TWI406658B (zh) 使用異硫氰酸酯類來治療癌症之方法及用途
HK40048076B (zh) 抗癌组合物
KR20210013573A (ko) 파라세타몰: 아미트리프틸린의 고정 용량 조성물 및 혼합 암 통증의 치료방법
Bakr THE EFFECT OF LOCAL WOUND INFILTERATION VERSUS CAUDAL BLOCK ON WOUND INFECTION AND HEALING AFTER INGUINAL HERNIOTOMY IN PAEDIATRICS
HK40028736A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000